File | |
language |
eng
|
Author |
Okimoto, Tamio
Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University, Japan
|
Description | A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with ceritinib as a fifth-line treatment. On day 54 after rechallenge, the patient developed acutely deteriorating dyspnea. Chest computed tomography showed extensive ground-glass opacities. We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy. To our knowledge, this is the first report of ceritinib-induced ILD in a Japanese patient. Since it may newly emerge with rechallenge therapy, close attention is necessary.
|
Subject | ceritinib
interstitial lung disease
anaplastic lymphoma kinase
adverse event
|
Journal Title |
Internal medicine
|
Volume | 59
|
Issue | 2
|
Start Page | 253
|
End Page | 256
|
ISSN | 0918-2918
|
ISSN(Online) | 1349-7235
|
Published Date | 2019
|
DOI | |
Publisher | 一般社団法人 日本内科学会
|
Publisher Transcription | イッパン シャダンホウジン ニホン ナイカ ガッカイ
|
Publisher Aalternative | The Japanese Society of Internal Medicine
|
NII Type |
Journal Article
|
Format |
PDF
|
Text Version |
著者版
|
Gyoseki ID | e38014
|
OAI-PMH Set |
Faculty of Medicine
|